Aura Biosciences (NASDAQ:AURA) Stock Price Down 4.9% After Insider Selling

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) traded down 4.9% on Tuesday following insider selling activity. The company traded as low as $11.01 and last traded at $11.08. 53,228 shares changed hands during trading, a decline of 70% from the average session volume of 175,820 shares. The stock had previously closed at $11.65.

Specifically, CFO Julie B. Feder sold 25,131 shares of Aura Biosciences stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.03, for a total value of $302,325.93. Following the transaction, the chief financial officer now directly owns 134,276 shares in the company, valued at $1,615,340.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Los Pinos Elisabet De sold 24,992 shares of Aura Biosciences stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.04, for a total value of $300,903.68. Following the completion of the transaction, the insider now owns 329,847 shares in the company, valued at $3,971,357.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In related news, CTO Mark Plavsic sold 7,383 shares of Aura Biosciences stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the transaction, the chief technology officer now directly owns 121,132 shares in the company, valued at $1,193,150.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. HC Wainwright lifted their target price on Aura Biosciences from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. BTIG Research lifted their price target on Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a report on Friday, October 18th. Scotiabank lifted their price target on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a report on Friday, October 18th. Finally, JMP Securities lifted their price target on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, September 13th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Aura Biosciences has a consensus rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Stock Down 2.2 %

The stock has a market cap of $564.29 million, a price-to-earnings ratio of -6.12 and a beta of 0.37. The business has a 50-day moving average of $8.80 and a 200-day moving average of $8.13.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.04. Equities analysts anticipate that Aura Biosciences, Inc. will post -1.7 earnings per share for the current year.

Institutional Trading of Aura Biosciences

Institutional investors have recently bought and sold shares of the company. American Century Companies Inc. acquired a new stake in Aura Biosciences during the second quarter valued at $119,000. American International Group Inc. boosted its position in Aura Biosciences by 27.4% during the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after purchasing an additional 3,782 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Aura Biosciences in the first quarter worth about $144,000. SG Americas Securities LLC acquired a new stake in shares of Aura Biosciences in the third quarter worth about $169,000. Finally, Rhumbline Advisers lifted its position in shares of Aura Biosciences by 39.6% in the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock worth $480,000 after buying an additional 18,011 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.